Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.45B | 1.47B | 1.50B | 1.26B | 1.69B | 1.29B |
Gross Profit | 844.00M | 899.11M | 953.69M | 864.58M | 1.36B | 1.08B |
EBITDA | -79.54M | -38.39M | -14.96M | -55.72M | 63.39M | -42.61M |
Net Income | -601.42M | -589.53M | 21.28M | -66.11M | -37.64M | 5.81M |
Balance Sheet | ||||||
Total Assets | 2.64B | 2.74B | 3.21B | 3.20B | 3.33B | 3.29B |
Cash, Cash Equivalents and Short-Term Investments | 1.02B | 1.19B | 1.33B | 1.57B | 1.74B | 2.65B |
Total Debt | 247.26M | 239.88M | 145.77M | 71.26M | 105.89M | 132.51M |
Total Liabilities | 743.60M | 776.43M | 653.25M | 590.00M | 813.33M | 672.44M |
Stockholders Equity | 1.78B | 1.84B | 2.44B | 2.50B | 2.45B | 2.60B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -88.18M | -28.68M | -128.58M | 39.23M | 142.22M |
Operating Cash Flow | 0.00 | -25.63M | 22.50M | -112.87M | 84.29M | 179.18M |
Investing Cash Flow | 0.00 | 257.04M | -202.61M | -572.21M | 339.82M | 123.84M |
Financing Cash Flow | 0.00 | -21.51M | -100.02M | -13.59M | -216.74M | -5.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | 859.59M | 43.59 | 5.80% | 0.42% | 3.50% | 13.99% | |
71 Outperform | 499.85M | 7.56 | 35.65% | ― | 141.25% | 0.00% | |
54 Neutral | 919.79M | -1.36 | 1662.26% | ― | -2.03% | 43.59% | |
52 Neutral | 582.75M | -1.54 | -74.11% | ― | -5.24% | 23.59% | |
49 Neutral | 197.75M | -1.86 | -28.81% | ― | 5.55% | -0.99% | |
47 Neutral | $390.33M | 17.80 | -31.64% | 0.67% | -5.43% | -2022.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 15, 2025, So-Young International Inc. announced its unaudited financial results for the second quarter ending June 30, 2025. The company reported total revenues of RMB378.7 million, a 7% decrease from the previous year, mainly due to a decline in medical service providers subscribing to its platform. Despite this, revenues from aesthetic treatment services surged by 426.1% due to the expansion of branded aesthetic centers. The company recorded a net loss of RMB36.0 million, contrasting with a net income of RMB18.9 million in the same period of 2024. Operational highlights included a significant increase in verified treatment visits and the number of active users. So-Young’s CEO highlighted the company’s strategic transformation, with branded aesthetic centers becoming the largest revenue contributor, and plans to expand the network to 50 centers by year-end.
So-Young International Inc. announced on July 3, 2025, that it has regained compliance with the Nasdaq’s minimum bid price requirement of $1.00 per share. This compliance follows a period of non-compliance that began on August 28, 2024, when the company’s American depositary shares fell below the required price for 30 consecutive business days. After receiving an extension from Nasdaq, the company successfully met the requirement by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days from June 17 to July 1, 2025. This development closes the compliance matter with Nasdaq, potentially stabilizing So-Young’s market position and reassuring stakeholders.
On June 20, 2025, So-Young International Inc. announced an amendment to the effective date for its previously planned ADS ratio change. The company initially intended to change the ratio of its American depositary shares (ADSs) to Class A ordinary shares from 13 ADSs representing 10 Class A shares to 1 ADS representing 15 Class A shares, with the change set for June 30, 2025. However, the company has decided to take additional time to finalize preparations, with a new timeline to be announced later. This change is expected to result in a proportional reverse ADS split, potentially increasing the ADS price, although no assurance is given regarding the price outcome. The ADSs will continue to trade on Nasdaq under the symbol ‘SY’.